title: [Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell].
abstract: OBJECTIVE
  To evaluate effectiveness of treatment with plerixafor in patients undergoing posterior mobilization for hematopoietic transplant at our hospital.
  
  
  METHODS
  Retrospective study of all patients who until September 2012, received plerixafor in their scheme of mobilization into peripheral blood hematopoietic progenitors. We reviewed the medical records and records of drug dispensing outpatient consultation. Effectiveness variables used were: CD34/kg in apheresis product obtained, and day dose received colony stimulating factor (G-CSF) and Plerixafor. Each patient was compared to the effectiveness of the drug results with those obtained earlier mobilization schemes where Plerixafor not used, if present. Data were analyzed using IBM SPSS v19.
  
  
  RESULTS
  A total of 24 patients received plerixafor in our hospital. Diagnoses were distributed: 15 NHL, 6 patients with multiple myeloma, 2 Hodgkin's disease, and one metastatic choriocarcinoma. The effectiveness outcomes were no plerixafor mobilization (n = 18): 5 patients were mobilized with G-CSGF only, 13 with G-CSF and chemotherapy. The G-CSF dose / day was mcg 931.1 (± 179.5) for 9.5 days (± 4.7). The average product obtained CD34/kg in cells was 0.2 (± 0.5). No patient received sufficient product (≥ 2 x 106 cells/kg) for subsequent autologous transplantation. 100% of the demonstrations failed. Mobilization with plerixafor (n = 24): 13 patients were mobilized with GCSGF only, 11 with G-CSF and chemotherapy. The G-CSF dose/ day and averaged Plerixafor mcg 885.1 (± 240.1) and 19.8 (± 4.4), respectively, administered for 8.9 (± 5.1) and 1 , 5 (± 0.6) days, respectively. The average product obtained in CD34/kg was 2.3 x 106 cells (± 1.7) (p = 0.014 in relation to the demonstrations without Plerixafor). Only 12.5% (n = 3) patients were unable to undergo autologous transplant.
  
  
  CONCLUSIONS
  In our patients, plerixafor has proven effective in mobilizing hematopoietic progenitors for autologous back.
authors.forename: R
authors.initials: R
authors.lastname: Ruano Camps
authors.forename: M
authors.initials: M
authors.lastname: Ortiz Pareja
authors.forename: I
authors.initials: I
authors.lastname: Vidales Mancha
authors.forename: I M
authors.initials: IM
authors.lastname: Muñoz Castillo
authors.forename: A I
authors.initials: AI
authors.lastname: Heiniger Mazo
mesh_terms: D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use; D001596:Benzylamines; D001772:Blood Cell Count; D001781:Blood Component Removal; D002822:Choriocarcinoma / Q000097:blood / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D003131:Combined Modality Therapy; D000080027:Cyclams; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D019337:Hematologic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000601:surgery; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006571:Heterocyclic Compounds / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011247:Pregnancy; D012189:Retrospective Studies; D014182:Transplantation, Autologous; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy
chemical_list: D018952:Antigens, CD34; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor